Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Offers FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q
January 23, 2020 6:39 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $168.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's 4Q earnings report. Chen continues to believe that upward earnings revisions to JNJ's Pharma business and multiple expansion, driven by diminishing headlines... More
Johnson & Johnson (JNJ) PT Raised to $170 at Credit Suisse
January 23, 2020 6:16 AM ESTCredit Suisse analyst Matt Miksic raised the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $163.00) while maintaining a Outperform rating.
The analyst comments "We continue to see strength in JNJs Pharma franchise and pipeline, and expect generic headwinds to ease in 2020 vs. 2019.... More
